XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses:        
Research and development $ 102,696 $ 91,399 $ 218,923 $ 198,415
General and administrative 32,267 25,194 61,620 50,430
Total operating expenses 134,963 116,593 280,543 248,845
Gain from divestiture of small molecule programs 0 0 0 14,537
Loss from operations (134,963) (116,593) (280,543) (234,308)
Interest and other income, net 10,844 17,567 23,454 33,480
Net loss $ (124,119) $ (99,026) $ (257,089) $ (200,828)
Net loss per share, basic (usd per share) $ (0.72) $ (0.59) $ (1.50) $ (1.26)
Net loss per share, diluted (usd per share) $ (0.72) $ (0.59) $ (1.50) $ (1.26)
Weighted average number of shares outstanding, basic (in shares) 171,449,847 168,831,329 171,336,568 159,117,759
Weighted average number of shares outstanding, diluted (in shares) 171,449,847 168,831,329 171,336,568 159,117,759
Comprehensive loss        
Net loss $ (124,119) $ (99,026) $ (257,089) $ (200,828)
Other comprehensive loss:        
Net unrealized loss on marketable securities, net of tax (1,098) (1,363) (1,081) (3,302)
Comprehensive loss $ (125,217) $ (100,389) $ (258,170) $ (204,130)